3 results
The primary objective of this study is to demonstrate that eritoran tetrasodium treatment of patients with severe sepsis results in a reduction in 28-day all-cause mortality.The secondary objectives are to confirm eritoran*s safety profile, and to…
CAEB071A2206 will assess safety, efficacy and target trough levels for optimal dosing of AEB071 combined with Certican in a CNI-free regimen in de novo renal transplant recipients. This study will combine the investigational drug AEB071 with an…
The purpose of this extension is to provide continued treatment and to assess the long term safety, efficacy and tolerability of oral AEB071 plus Certican® vs. Neoral® plus Certican® in de novo renal transplant recipients. The study is a…